Revelation Biosciences Inc (REVB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Revelation Biosciences Inc (REVB) has a cash flow conversion efficiency ratio of -0.144x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.59 Million) by net assets ($11.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Revelation Biosciences Inc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Revelation Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read REVB total debt and obligations for a breakdown of total debt and financial obligations.
Revelation Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Revelation Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Damon Inc. Common Stock
NASDAQ:DMN
|
0.392x |
|
Rocky Mountain Liquor Inc
V:RUM
|
0.141x |
|
Eastern Resources Ltd
AU:EFE
|
-0.010x |
|
Timah Resources Ltd
AU:TML
|
0.007x |
|
Next 15 Group PLC
LSE:NFG
|
0.023x |
|
Netcapital Inc
NASDAQ:NCPL
|
-0.120x |
|
Mid Wynd International Investment Trust plc
LSE:MWY
|
0.002x |
|
NetJobs Group AB
ST:NJOB
|
-0.675x |
Annual Cash Flow Conversion Efficiency for Revelation Biosciences Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Revelation Biosciences Inc from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see REVB company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $4.71 Million | $-18.32 Million | -3.891x | -255.02% |
| 2023-12-31 | $6.65 Million | $-7.29 Million | -1.096x | +89.72% |
| 2022-12-31 | $1.05 Million | $-11.22 Million | -10.660x | -109.56% |
| 2021-12-31 | $-99.47K | $-11.09 Million | 111.497x | +176962.24% |
| 2020-12-31 | $3.41 Million | $-215.07K | -0.063x | +100.00% |
| 2019-12-31 | $-3.64K | $41.09 Million | -11293.568x | -9182593.30% |
| 2018-12-31 | $264.89 Million | $32.58 Million | 0.123x | -4.50% |
| 2017-12-31 | $188.28 Million | $24.25 Million | 0.129x | +87.38% |
| 2016-12-31 | $168.76 Million | $11.60 Million | 0.069x | -- |
About Revelation Biosciences Inc
Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treat… Read more